(State of Organization) | (IRS Employer Identification No.) | ||||||||||
(Address of Principal Executive Offices) | (Zip Code) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Page Number | ||||||||
March 31, 2023 | December 31, 2022 | ||||||||||
(unaudited) | |||||||||||
ASSETS | |||||||||||
Investment properties: | |||||||||||
Land and improvements | $ | $ | |||||||||
Building and improvements | |||||||||||
Tenant improvements | |||||||||||
Acquired lease intangibles | |||||||||||
Accumulated depreciation | ( | ( | |||||||||
Net real estate property | |||||||||||
Right-of-use lease assets, net | |||||||||||
Real estate loans receivable, net | |||||||||||
Investments in unconsolidated entities | |||||||||||
Net real estate investments | |||||||||||
Cash and cash equivalents | |||||||||||
Tenant receivables, net | |||||||||||
Other assets | |||||||||||
Total assets | $ | $ | |||||||||
LIABILITIES AND EQUITY | |||||||||||
Liabilities: | |||||||||||
Credit facility | $ | $ | |||||||||
Notes payable | |||||||||||
Mortgage debt | |||||||||||
Accounts payable | |||||||||||
Dividends and distributions payable | |||||||||||
Accrued expenses and other liabilities | |||||||||||
Lease liabilities | |||||||||||
Acquired lease intangibles, net | |||||||||||
Total liabilities | |||||||||||
Redeemable noncontrolling interests - partially owned properties | |||||||||||
Equity: | |||||||||||
Common shares, $ | |||||||||||
Additional paid-in capital | |||||||||||
Accumulated deficit | ( | ( | |||||||||
Accumulated other comprehensive income | |||||||||||
Total shareholders’ equity | |||||||||||
Noncontrolling interests: | |||||||||||
Operating Partnership | |||||||||||
Partially owned properties | |||||||||||
Total noncontrolling interests | |||||||||||
Total equity | |||||||||||
Total liabilities and equity | $ | $ |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Revenues: | |||||||||||
Rental and related revenues | $ | $ | |||||||||
Interest income on real estate loans and other | |||||||||||
Total revenues | |||||||||||
Expenses: | |||||||||||
Interest expense | |||||||||||
General and administrative | |||||||||||
Operating expenses | |||||||||||
Depreciation and amortization | |||||||||||
Total expenses | |||||||||||
Income before equity in loss of unconsolidated entities and gain (loss) on sale of investment properties, net: | |||||||||||
Equity in loss of unconsolidated entities | ( | ( | |||||||||
Gain (loss) on sale of investment properties, net | ( | ||||||||||
Net income | |||||||||||
Net income attributable to noncontrolling interests: | |||||||||||
Operating Partnership | ( | ( | |||||||||
Partially owned properties (1) | ( | ( | |||||||||
Net income attributable to common shareholders | $ | $ | |||||||||
Net income per share: | |||||||||||
Basic | $ | $ | |||||||||
Diluted | $ | $ | |||||||||
Weighted average common shares: | |||||||||||
Basic | |||||||||||
Diluted | |||||||||||
Dividends and distributions declared per common share | $ | $ |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net income | $ | $ | |||||||||
Other comprehensive income: | |||||||||||
Change in fair value of interest rate swap agreements, net | ( | ||||||||||
Total other comprehensive (loss) income | ( | ||||||||||
Comprehensive income | |||||||||||
Comprehensive income attributable to noncontrolling interests - Operating Partnership | ( | ( | |||||||||
Comprehensive income attributable to noncontrolling interests - partially owned properties | ( | ( | |||||||||
Comprehensive income attributable to common shareholders | $ | $ |
Par Value | Additional Paid in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Shareholders’ Equity | Operating Partnership Noncontrolling Interest | Partially Owned Properties Noncontrolling Interest | Total Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2022 | $ | $ | $ | ( | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||
Net proceeds from sale of common shares | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted share award grants, net | ( | ( | — | ( | — | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||
Conversion of OP Units | — | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
Dividends/distributions declared | — | — | ( | — | ( | ( | — | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||
Contributions | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
Distributions | — | — | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||
Change in fair value of interest rate swap agreement | — | — | — | ( | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | ( | — | — | ( | — | |||||||||||||||||||||||||||||||||||||||||||||||
Net income | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2023 | $ | $ | $ | ( | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||
Par Value | Additional Paid in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Total Shareholders’ Equity | Operating Partnership Noncontrolling Interest | Partially Owned Properties Noncontrolling Interest | Total Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2021 | $ | $ | $ | ( | $ | ( | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
Net proceeds from sale of common shares | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
Restricted share award grants, net | ( | — | ( | — | — | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||
Purchase of OP Units | — | — | — | — | — | ( | — | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||
Dividends/distributions declared | — | — | ( | — | ( | ( | — | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||
Contributions | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
Distributions | — | — | — | — | — | — | ( | ( | ( | ||||||||||||||||||||||||||||||||||||||||||||
Change in market value of Redeemable Noncontrolling Interest in partially owned properties | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
Change in fair value of interest rate swap agreement | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | ( | — | — | ( | — | |||||||||||||||||||||||||||||||||||||||||||||||
Net income | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2022 | $ | $ | $ | ( | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Cash Flows from Operating Activities: | |||||||||||
Net income | $ | $ | |||||||||
Adjustments to reconcile net income to net cash provided by operating activities | |||||||||||
Depreciation and amortization | |||||||||||
Amortization of deferred financing costs | |||||||||||
Amortization of lease inducements and above/below-market lease intangibles | |||||||||||
Straight-line rental revenue, net | ( | ( | |||||||||
Amortization of discount on unsecured senior notes | |||||||||||
Amortization of above market assumed debt | ( | ||||||||||
(Gain) loss on sale of investment properties, net | ( | ||||||||||
Equity in loss of unconsolidated entities | |||||||||||
Distributions from unconsolidated entities | |||||||||||
Provision for bad debts | |||||||||||
Non-cash share compensation | |||||||||||
Change in operating assets and liabilities: | |||||||||||
Tenant receivables | ( | ||||||||||
Other assets | ( | ||||||||||
Accounts payable | ( | ( | |||||||||
Accrued expenses and other liabilities | ( | ( | |||||||||
Net cash provided by operating activities | |||||||||||
Cash Flows from Investing Activities: | |||||||||||
Proceeds from sale of investment properties | |||||||||||
Acquisition of investment properties, net | ( | ( | |||||||||
Investment in unconsolidated entities | ( | ( | |||||||||
Development of real estate | ( | ||||||||||
Escrowed cash - acquisition deposits/earnest deposits | |||||||||||
Capital expenditures on investment properties | ( | ( | |||||||||
Investment in real estate loans receivable | ( | ( | |||||||||
Repayment of real estate loans receivable | |||||||||||
Leasing commissions | ( | ( | |||||||||
Lease inducements | ( | ||||||||||
Net cash (used in) provided by investing activities | ( | ||||||||||
Cash Flows from Financing Activities: | |||||||||||
Net proceeds from sale of common shares | |||||||||||
Proceeds from credit facility borrowings | |||||||||||
Repayment of credit facility borrowings | ( | ( | |||||||||
Repayment of senior unsecured notes | ( | ||||||||||
Principal payments on mortgage debt | ( | ( | |||||||||
Debt issuance costs | ( | ( | |||||||||
Dividends paid - shareholders | ( | ( | |||||||||
Distributions to noncontrolling interests - Operating Partnership | ( | ( | |||||||||
Contributions from noncontrolling interest | |||||||||||
Distributions to noncontrolling interests - partially owned properties | ( | ( | |||||||||
Payments of employee taxes for withheld stock-based compensation shares | ( | ( | |||||||||
Purchase of OP Units | ( | ||||||||||
Net cash used in financing activities | ( | ( | |||||||||
Net decrease in cash and cash equivalents | ( | ( | |||||||||
Cash and cash equivalents, beginning of period | |||||||||||
Cash and cash equivalents, end of period | $ | $ | |||||||||
Supplemental disclosure of cash flow information—interest paid during the period | $ | $ | |||||||||
Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements | $ | ( | $ | ||||||||
Supplemental disclosure of noncash activity—conversion of loan receivable in connection to the acquisition of investment property | $ | $ | |||||||||
Land | $ | ||||
Building and improvements | |||||
Cash used in acquisition of investment property | $ |
March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||||||
Cost | Accumulated Amortization | Net | Cost | Accumulated Amortization | Net | ||||||||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||||
In-place leases | $ | $ | ( | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||
Above-market leases | $ | $ | ( | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||||||||
Below-market leases | $ | $ | ( | $ | $ | $ | ( | $ |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Amortization expense related to in-place leases | $ | $ | |||||||||
Decrease in rental income related to above-market leases | |||||||||||
Increase in rental income related to below-market leases |
Net Decrease (Increase) in Revenue | Net Increase in Expenses | ||||||||||
2023 | $ | $ | |||||||||
2024 | |||||||||||
2025 | |||||||||||
2026 | |||||||||||
2027 | |||||||||||
Thereafter | ( | ||||||||||
Total | $ | $ |
March 31, 2023 | December 31, 2022 | ||||||||||
Straight line rent receivable, net | $ | $ | |||||||||
Leasing commissions, net | |||||||||||
Prepaid expenses | |||||||||||
Lease inducements, net | |||||||||||
Interest rate swap | |||||||||||
Escrows | |||||||||||
Notes receivable, net | |||||||||||
Other | |||||||||||
Total | $ | $ |
March 31, 2023 | December 31, 2022 | ||||||||||
Fixed interest mortgage notes (1) | $ | $ | |||||||||
Variable interest mortgage notes (2) | |||||||||||
Total mortgage debt | |||||||||||
$ | |||||||||||
$ | |||||||||||
$ | |||||||||||
$ | |||||||||||
$ | |||||||||||
$ | |||||||||||
Total principal | |||||||||||
Unamortized deferred financing costs | ( | ( | |||||||||
Unamortized discounts | ( | ( | |||||||||
Total debt | $ | $ |
Credit Rating | Applicable Margin for Revolving Loans: SOFR Loans and Letter of Credit Fee | Applicable Margin for Revolving Loans: Base Rate Loans | Applicable Margin for Term Loans: SOFR Loans | Applicable Margin for Term Loans: Base Rate Loans | ||||||||||||||||||||||
At Least A- or A3 | SOFR + | % | SOFR + | % | ||||||||||||||||||||||
At Least BBB+ or Baa1 | SOFR + | % | SOFR + | % | ||||||||||||||||||||||
At Least BBB or Baa2 | SOFR + | % | SOFR + | % | ||||||||||||||||||||||
At Least BBB- or Baa3 | SOFR + | % | SOFR + | % | ||||||||||||||||||||||
Below BBB- or Baa3 | SOFR + | % | SOFR + | % |
2023 | $ | ||||
2024 | |||||
2025 | |||||
2026 | |||||
2027 | |||||
Thereafter | |||||
Total Payments | $ |
Total notional amount | $ | |||||||
Effective fixed interest rate | (1) | % | ||||||
Effective date | ||||||||
Maturity date | ||||||||
Asset balance at March 31, 2023 (included in Other assets) | $ | |||||||
Asset balance at December 31, 2022 (included in Other assets) | $ |
March 31, 2023 | December 31, 2022 | ||||||||||
Prepaid rent | $ | $ | |||||||||
Real estate taxes payable | |||||||||||
Accrued interest | |||||||||||
Accrued expenses | |||||||||||
Security deposits | |||||||||||
Accrued incentive compensation | |||||||||||
Tenant improvement allowances | |||||||||||
Other | |||||||||||
Total | $ | $ |
Common Shares | Weighted Average Grant Date Fair Value | ||||||||||
Non-vested at December 31, 2022 | $ | ||||||||||
Granted | |||||||||||
Vested | ( | ||||||||||
Forfeited | ( | ||||||||||
Non-vested at March 31, 2023 | $ |
Volatility | % | ||||
Dividend assumption | reinvested | ||||
Expected term in years | |||||
Risk-free rate | % | ||||
Share price (per share) | $ |
Executive Awards | Trustee Awards | ||||||||||||||||||||||
Restricted Share Units | Weighted Average Grant Date Fair Value | Restricted Share Units | Weighted Average Grant Date Fair Value | ||||||||||||||||||||
Non-vested at December 31, 2022 | $ | $ | |||||||||||||||||||||
Granted | |||||||||||||||||||||||
Vested | ( | (1) | ( | ||||||||||||||||||||
Non-vested at March 31, 2023 | $ | $ |
March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | ||||||||||||||||||||
Assets: | |||||||||||||||||||||||
Real estate loans receivable, net | $ | $ | $ | $ | |||||||||||||||||||
Notes receivable, net | $ | $ | $ | $ | |||||||||||||||||||
Derivative assets | $ | $ | $ | $ | |||||||||||||||||||
Liabilities: | |||||||||||||||||||||||
Credit facility | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Notes payable | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
Mortgage debt | $ | ( | $ | ( | $ | ( | $ | ( | |||||||||||||||
2023 | $ | ||||
2024 | |||||
2025 | |||||
2026 | |||||
2027 | |||||
Thereafter | |||||
Total | $ |
2023 | $ | ||||
2024 | |||||
2025 | |||||
2026 | |||||
2027 | |||||
Thereafter | |||||
Total undiscounted lease payments | $ | ||||
Less: Interest | ( | ||||
Present value of lease liabilities | $ |
Fixed lease cost | $ | ||||
Variable lease cost | |||||
Total lease cost | $ |
Tenant | Total ABR | Percent of ABR | ||||||||||||
CommonSpirit - CHI - Nebraska | $ | % | ||||||||||||
Northside Hospital | % | |||||||||||||
UofL Health - Louisville, Inc. | % | |||||||||||||
US Oncology | % | |||||||||||||
HonorHealth | % | |||||||||||||
Remaining portfolio | % | |||||||||||||
Total | $ | % |
State | Total ABR | Percent of ABR | ||||||||||||
Texas | $ | % | ||||||||||||
Georgia | % | |||||||||||||
Florida | % | |||||||||||||
Indiana | % | |||||||||||||
Arizona | % | |||||||||||||
Other | % | |||||||||||||
Total | $ | % |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Numerator for earnings per share - basic: | |||||||||||
Net income | $ | $ | |||||||||
Net income attributable to noncontrolling interests: | |||||||||||
Operating Partnership | ( | ( | |||||||||
Partially owned properties | ( | ( | |||||||||
Numerator for earnings per share - basic | $ | $ | |||||||||
Numerator for earnings per share - diluted: | |||||||||||
Numerator for earnings per share - basic | $ | $ | |||||||||
Noncontrolling interest - Operating Partnership income | |||||||||||
Numerator for earnings per share - diluted | $ | $ | |||||||||
Denominator for earnings per share - basic and diluted: | |||||||||||
Weighted average number of shares outstanding - basic | |||||||||||
Effect of dilutive securities: | |||||||||||
Noncontrolling interest - Operating Partnership units | |||||||||||
Restricted common shares | |||||||||||
Restricted share units | |||||||||||
Denominator for earnings per share - diluted: | |||||||||||
Earnings per share - basic | $ | $ | |||||||||
Earnings per share - diluted | $ | $ |
2023 | 2022 | Change | % | ||||||||||||||||||||
Revenues: | |||||||||||||||||||||||
Rental and related revenues | $ | 131,398 | $ | 127,791 | $ | 3,607 | 2.8 | % | |||||||||||||||
Interest income on real estate loans and other | 2,946 | 2,599 | 347 | 13.4 | % | ||||||||||||||||||
Total revenues | 134,344 | 130,390 | 3,954 | 3.0 | % | ||||||||||||||||||
Expenses: | |||||||||||||||||||||||
Interest expense | 19,153 | 16,823 | 2,330 | 13.9 | % | ||||||||||||||||||
General and administrative | 11,200 | 10,293 | 907 | 8.8 | % | ||||||||||||||||||
Operating expenses | 45,394 | 41,752 | 3,642 | 8.7 | % | ||||||||||||||||||
Depreciation and amortization | 47,677 | 47,260 | 417 | 0.9 | % | ||||||||||||||||||
Total expenses | 123,424 | 116,128 | 7,296 | 6.3 | % | ||||||||||||||||||
Income before equity in loss of unconsolidated entities and gain (loss) on sale of investment properties, net: | 10,920 | 14,262 | (3,342) | (23.4) | % | ||||||||||||||||||
Equity in loss of unconsolidated entities | (264) | (166) | (98) | NM | |||||||||||||||||||
Gain (loss) on sale of investment properties, net | 13 | (153) | 166 | NM | |||||||||||||||||||
Net income | $ | 10,669 | $ | 13,943 | $ | (3,274) | (23.5) | % |
2023 | 2022 | Change | % | ||||||||||||||||||||
Rental revenues | $ | 93,543 | $ | 92,665 | $ | 878 | 0.9 | % | |||||||||||||||
Expense recoveries | 37,855 | 35,126 | 2,729 | 7.8 | % | ||||||||||||||||||
Rental and related revenues | $ | 131,398 | $ | 127,791 | $ | 3,607 | 2.8 | % |
2023 | 2022 | ||||||||||
Cash provided by operating activities | $ | 63,719 | $ | 54,535 | |||||||
Cash (used in) provided by investing activities | (21,768) | 12,181 | |||||||||
Cash used in financing activities | (46,317) | (73,863) | |||||||||
Decrease in cash and cash equivalents | $ | (4,366) | $ | (7,147) |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net income | $ | 10,669 | $ | 13,943 | |||||||
Earnings per share - diluted | $ | 0.04 | $ | 0.06 | |||||||
Net income | $ | 10,669 | $ | 13,943 | |||||||
Net income attributable to noncontrolling interests - partially owned properties | (44) | (159) | |||||||||
Depreciation and amortization expense | 47,560 | 47,149 | |||||||||
Depreciation and amortization expense - partially owned properties | (138) | (70) | |||||||||
(Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
Proportionate share of unconsolidated joint venture adjustments | 2,306 | 2,383 | |||||||||
FFO applicable to common shares | $ | 60,340 | $ | 63,399 | |||||||
Proportionate share of unconsolidated joint venture adjustments | — | (8) | |||||||||
Normalized FFO applicable to common shares | $ | 60,340 | $ | 63,391 | |||||||
FFO per common share - diluted | $ | 0.24 | $ | 0.27 | |||||||
Normalized FFO per common share - diluted | $ | 0.24 | $ | 0.27 | |||||||
Weighted average common shares outstanding - diluted | 248,756,672 | 238,340,243 |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net income | $ | 10,669 | $ | 13,943 | |||||||
Normalized FFO applicable to common shares | $ | 60,340 | $ | 63,391 | |||||||
Normalized FFO applicable to common shares | $ | 60,340 | $ | 63,391 | |||||||
Non-cash share compensation expense | 4,667 | 4,253 | |||||||||
Straight-line rent adjustments | (1,235) | (2,154) | |||||||||
Amortization of acquired above/below-market leases/assumed debt | 1,135 | 1,339 | |||||||||
Amortization of lease inducements | 229 | 225 | |||||||||
Amortization of deferred financing costs | 569 | 579 | |||||||||
Recurring capital expenditures and lease commissions | (5,786) | (5,663) | |||||||||
Loan reserve adjustments | 3 | 3 | |||||||||
Proportionate share of unconsolidated joint venture adjustments | (219) | (431) | |||||||||
Normalized FAD applicable to common shares | $ | 59,703 | $ | 61,542 |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net income | $ | 10,669 | $ | 13,943 | |||||||
General and administrative | 11,200 | 10,293 | |||||||||
Depreciation and amortization expense | 47,677 | 47,260 | |||||||||
Interest expense | 19,153 | 16,823 | |||||||||
(Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
Proportionate share of unconsolidated joint venture adjustments | 3,644 | 3,422 | |||||||||
NOI | $ | 92,330 | $ | 91,894 | |||||||
NOI | $ | 92,330 | $ | 91,894 | |||||||
Straight-line rent adjustments | (1,235) | (2,154) | |||||||||
Amortization of acquired above/below-market leases | 1,135 | 1,349 | |||||||||
Amortization of lease inducements | 229 | 225 | |||||||||
Loan reserve adjustments | 3 | 3 | |||||||||
Proportionate share of unconsolidated joint venture adjustments | (108) | (71) | |||||||||
Cash NOI | $ | 92,354 | $ | 91,246 | |||||||
Cash NOI | $ | 92,354 | $ | 91,246 | |||||||
Assets not held for all periods or held for sale | (1,458) | (1,504) | |||||||||
Non-MOB health care properties | (2,798) | (2,758) | |||||||||
Lease termination fees | (31) | (4) | |||||||||
Interest income on real estate loans | (2,282) | (2,199) | |||||||||
Joint venture and other income | (3,768) | (3,576) | |||||||||
MOB Same-Store Cash NOI | $ | 82,017 | $ | 81,205 |
Three Months Ended March 31, | |||||||||||
2023 | 2022 | ||||||||||
Net income | $ | 10,669 | $ | 13,943 | |||||||
Depreciation and amortization expense | 47,677 | 47,260 | |||||||||
Interest expense | 19,153 | 16,823 | |||||||||
(Gain) loss on sale of investment properties, net | (13) | 153 | |||||||||
Proportionate share of unconsolidated joint venture adjustments | 3,590 | 3,420 | |||||||||
EBITDAre | $ | 81,076 | $ | 81,599 | |||||||
Non-cash share compensation expense | 4,667 | 4,253 | |||||||||
Pursuit costs | 63 | 74 | |||||||||
Non-cash intangible amortization | 1,364 | 1,575 | |||||||||
Proportionate share of unconsolidated joint venture adjustments | — | (8) | |||||||||
Pro forma adjustments for investment activity | 89 | 68 | |||||||||
Adjusted EBITDAre | $ | 87,259 | $ | 87,561 |
Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | ||||||||||||||||||||||
January 1, 2023 - January 31, 2023 | 167,779 | (1) | $ | 14.42 | N/A | N/A | ||||||||||||||||||||
February 1, 2023 - February 28, 2023 | 290,380 | (2) | 15.07 | N/A | N/A | |||||||||||||||||||||
March 1, 2023 - March 31, 2023 | 92,895 | (2) | 14.70 | N/A | N/A | |||||||||||||||||||||
Total | 551,054 | $ | 14.81 | — | — |
Exhibit No. | Description | |||||||
(1) | ||||||||
101.INS | This instance document does not appear in the interactive data file because of XBRL tags are embedded within the inline XBRL document. | |||||||
101.SCH | Inline XBRL Extension Schema Document (+) | |||||||
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document (+) | |||||||
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document (+) | |||||||
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document (+) | |||||||
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document (+) | |||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
PHYSICIANS REALTY TRUST | |||||
Date: May 4, 2023 | /s/ John T. Thomas | ||||
John T. Thomas | |||||
President and Chief Executive Officer | |||||
(Principal Executive Officer) | |||||
Date: May 4, 2023 | /s/ Jeffrey N. Theiler | ||||
Jeffrey N. Theiler | |||||
Executive Vice President and Chief Financial Officer | |||||
(Principal Financial Officer) |
Debt Instrument | Issuer | ||||
4.300% Senior Notes due 2027 | Physicians Realty L.P. | ||||
3.950% Senior Notes due 2028 | Physicians Realty L.P. | ||||
2.625% Senior Notes due 2031 | Physicians Realty L.P. |
Date: May 4, 2023 | /s/ John T. Thomas | ||||
John T. Thomas | |||||
President and Chief Executive Officer |
Date: May 4, 2023 | /s/ Jeffrey N. Theiler | ||||
Jeffrey N. Theiler | |||||
Executive Vice President and Chief Financial Officer |
/s/ John T. Thomas | |||||
John T. Thomas | |||||
President and Chief Executive Officer | |||||
/s/ Jeffrey N. Theiler | |||||
Jeffrey N. Theiler | |||||
Executive Vice President and Chief Financial Officer |
Consolidated Balance Sheets (Parenthetical) - $ / shares |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Equity: | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, shares outstanding (in shares) | 238,395,869 | 233,292,030 |
Common stock, shares issued (in shares) | 238,395,869 | 233,292,030 |
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 10,669 | $ 13,943 |
Other comprehensive income: | ||
Change in fair value of interest rate swap agreements, net | (1,021) | 1,379 |
Total other comprehensive (loss) income | (1,021) | 1,379 |
Comprehensive income | 9,648 | 15,322 |
Comprehensive income attributable to noncontrolling interests - Operating Partnership | (383) | (761) |
Comprehensive income attributable to noncontrolling interests - partially owned properties | (44) | (159) |
Comprehensive income attributable to common shareholders | $ 9,221 | $ 14,402 |
Consolidated Statement of Equity - USD ($) $ in Thousands |
Total |
Total Shareholders’ Equity |
Par Value |
Additional Paid in Capital |
Accumulated Deficit |
Accumulated Other Comprehensive Income (Loss) |
Total Noncontrolling Interests |
Operating Partnership Noncontrolling Interest |
Partially Owned Properties Noncontrolling Interest |
---|---|---|---|---|---|---|---|---|---|
Balance at beginning of period at Dec. 31, 2021 | $ 2,987,033 | $ 2,836,308 | $ 2,247 | $ 3,610,954 | $ (776,001) | $ (892) | $ 150,725 | $ 150,241 | $ 484 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net proceeds from sale of common shares | 5,032 | 5,032 | 3 | 5,029 | |||||
Restricted share award grants, net | (300) | (300) | 3 | 118 | (421) | ||||
Purchase of OP Units | (184) | (184) | (184) | ||||||
Dividends/distributions declared | (54,619) | (51,879) | (51,879) | (2,740) | (2,740) | ||||
Contributions | 569 | 569 | 569 | ||||||
Distributions | (55) | (55) | (55) | ||||||
Change in market value of Redeemable Noncontrolling Interest in partially owned properties | 717 | 717 | 717 | ||||||
Change in fair value of interest rate swap agreements | 1,379 | 1,379 | 1,379 | ||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (217) | (217) | 217 | 217 | ||||
Net income | 13,866 | 13,092 | 13,092 | 774 | 692 | 82 | |||
Balance at end of period at Mar. 31, 2022 | 2,953,438 | 2,804,132 | 2,253 | 3,615,884 | (814,492) | 487 | 149,306 | 148,226 | 1,080 |
Balance at beginning of period at Dec. 31, 2022 | 2,993,851 | 2,869,720 | 2,333 | 3,743,876 | (881,672) | 5,183 | 124,131 | 123,015 | 1,116 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||
Net proceeds from sale of common shares | 65,813 | 65,813 | 44 | 65,769 | |||||
Restricted share award grants, net | (1,530) | (1,530) | 5 | (1,127) | (408) | ||||
Conversion of OP Units | 0 | 2,419 | 2 | 2,417 | (2,419) | (2,419) | |||
Dividends/distributions declared | (57,175) | (54,912) | (54,912) | (2,263) | (2,263) | ||||
Contributions | 7,884 | 7,884 | 7,884 | ||||||
Distributions | (53) | (53) | (53) | ||||||
Change in fair value of interest rate swap agreements | (1,021) | (1,021) | (1,021) | ||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | 0 | (431) | (431) | 431 | 431 | ||||
Net income | 10,689 | 10,202 | 10,202 | 487 | 423 | 64 | |||
Balance at end of period at Mar. 31, 2023 | $ 3,018,458 | $ 2,890,260 | $ 2,384 | $ 3,810,504 | $ (926,790) | $ 4,162 | $ 128,198 | $ 119,187 | $ 9,011 |
Consolidated Statements of Cash Flows - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Cash Flows from Operating Activities: | ||
Net income | $ 10,669 | $ 13,943 |
Adjustments to reconcile net income to net cash provided by operating activities | ||
Depreciation and amortization | 47,677 | 47,260 |
Amortization of deferred financing costs | 569 | 579 |
Amortization of lease inducements and above/below-market lease intangibles | 1,364 | 1,575 |
Straight-line rental revenue, net | (1,235) | (2,154) |
Amortization of discount on unsecured senior notes | 272 | 262 |
Amortization of above market assumed debt | 0 | (10) |
(Gain) loss on sale of investment properties, net | (13) | 153 |
Equity in loss of unconsolidated entities | 264 | 166 |
Distributions from unconsolidated entities | 1,906 | 2,002 |
Provision for bad debts | 281 | 87 |
Non-cash share compensation | 4,667 | 4,253 |
Change in operating assets and liabilities: | ||
Tenant receivables | 567 | (791) |
Other assets | 536 | (266) |
Accounts payable | (1,048) | (5,252) |
Accrued expenses and other liabilities | (2,757) | (7,272) |
Net cash provided by operating activities | 63,719 | 54,535 |
Cash Flows from Investing Activities: | ||
Proceeds from sale of investment properties | 2,553 | 1,804 |
Acquisition of investment properties, net | (2,650) | (10) |
Investment in unconsolidated entities | (180) | (5,045) |
Development of real estate | (953) | 0 |
Escrowed cash - acquisition deposits/earnest deposits | 0 | 90 |
Capital expenditures on investment properties | (8,400) | (5,491) |
Investment in real estate loans receivable | (10,956) | (904) |
Repayment of real estate loans receivable | 0 | 22,441 |
Leasing commissions | (782) | (704) |
Lease inducements | (400) | 0 |
Net cash (used in) provided by investing activities | (21,768) | 12,181 |
Cash Flows from Financing Activities: | ||
Net proceeds from sale of common shares | 65,813 | 5,032 |
Proceeds from credit facility borrowings | 55,000 | 64,000 |
Repayment of credit facility borrowings | (96,000) | (83,000) |
Repayment of senior unsecured notes | (15,000) | 0 |
Principal payments on mortgage debt | (253) | (420) |
Debt issuance costs | (14) | (10) |
Dividends paid - shareholders | (55,643) | (52,858) |
Distributions to noncontrolling interests - Operating Partnership | (2,264) | (2,739) |
Contributions from noncontrolling interest | 7,884 | 569 |
Distributions to noncontrolling interests - partially owned properties | (98) | (161) |
Payments of employee taxes for withheld stock-based compensation shares | (5,742) | (4,092) |
Purchase of OP Units | 0 | (184) |
Net cash used in financing activities | (46,317) | (73,863) |
Net decrease in cash and cash equivalents | (4,366) | (7,147) |
Cash and cash equivalents, beginning of period | 7,730 | 9,876 |
Cash and cash equivalents, end of period | 3,364 | 2,729 |
Supplemental Cash Flow Information [Abstract] | ||
Supplemental disclosure of cash flow information - interest paid during the period | 25,176 | 23,123 |
Supplemental disclosure of noncash activity—change in fair value of interest rate swap agreements | (1,021) | 1,379 |
Supplemental disclosure of noncash activity—conversion of loan receivable in connection to the acquisition of investment property | $ 0 | $ 3,000 |
Organization and Business |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business | Organization and Business Physicians Realty Trust (the “Trust” or the “Company”) was organized in the state of Maryland on April 9, 2013. As of March 31, 2023, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share. The Trust filed a Registration Statement on Form S-11 with the Commission with respect to a proposed underwritten initial public offering (the “IPO”) and completed the IPO of its common shares and commenced operations on July 24, 2013. The Trust contributed the net proceeds from the IPO to Physicians Realty L.P, a Delaware limited partnership (the “Operating Partnership”), and is the sole general partner of the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership. The Trust is a self-managed REIT formed primarily to acquire, selectively develop, own, and manage health care properties that are leased to physicians, hospitals, and health care delivery systems. ATM Program In May 2021, the Trust and the Operating Partnership entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., BMO Capital Markets Corp., and Raymond James & Associates, Inc. in their capacity as agents for the Company and/or forward sellers and Stifel, Nicolaus & Company, Incorporated in its capacity as sales agent for the Company (collectively, the “Agents”) and Bank of Montreal, Credit Agricole Corporate and Investments Bank, KeyBanc Capital Markets Inc., and Raymond James & Associates, Inc. as forward purchasers for the Company (the “Forward Purchasers”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $500 million through the Agents (the “ATM Program”). The Sales Agreement contemplates that, in addition to the issuance and sale of the Trust’s common shares through the Agents, the Trust may also enter into one or more forward sales agreements from time to time in the future with each of the Forward Purchasers. During the quarterly period ended March 31, 2023, the Trust sold 4,400,000 common shares pursuant to the ATM Program, at a weighted average price of $15.10 per share, resulting in total net proceeds of approximately $65.8 million. As of March 31, 2023, the Trust had $158.6 million remaining available under the ATM Program.
|
Summary of Significant Accounting Policies |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies The accompanying unaudited consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the periods ended March 31, 2023 and 2022 pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited financial statements included in the Trust’s 2022 Annual Report. The Company has consistently applied its accounting policies to all periods presented in these consolidated financial statements. Noncontrolling Interests The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets. Operating Partnership: Noncontrolling interests in the Company include OP Units held by other investors. Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions. As of March 31, 2023, the Trust held a 96.0% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership. Partially Owned Properties: The Trust reflects noncontrolling interests in partially owned properties on the consolidated balance sheets for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income. Redeemable Noncontrolling Interests - Partially Owned Properties In connection with the Company’s acquisitions of the medical office building, ambulatory surgery center, and hospital located on the Great Falls Hospital campus in Great Falls, Montana, physicians affiliated with the sellers retained non-controlling interests which were, at the holders’ option, able to be redeemed at any time after May 1, 2023. Due to the redemption provision, which was outside of the control of the Trust, the Trust classified the investment in the mezzanine section of its consolidated balance sheets. On July 14, 2022, the Company disposed of these three properties and removed the related redeemable noncontrolling interests from its consolidated balance sheets. Through a consolidated joint venture with MedProperties Realty Advisors, LLC (“MedProperties”), the Company acquired Calko Medical Center in Brooklyn, New York. As part of the joint venture, MedProperties can redeem its interest, at its option, at any time after September 9, 2025. Due to the redemption provision, which is outside of the control of the Company, the Company classifies the noncontrolling interests in the mezzanine section of its consolidated balance sheets. The Company records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value. Dividends and Distributions On March 17, 2023, the Trust announced that its Board of Trustees authorized, and the Trust declared, a cash dividend of $0.23 per common share for the quarter ended March 31, 2023. The dividend was paid on April 18, 2023 to common shareholders and holders of record of partnership interests of the Operating Partnership (“OP Units”) as of the close of business on April 4, 2023. Tax Status of Dividends and Distributions The Company’s distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain. Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units). The Company has elected taxable REIT subsidiary (“TRS”) status for certain of its corporate subsidiaries and, as a result, these entities will incur both federal and state income taxes on any taxable income of such entities after consideration of any net operating losses. To date, these income taxes have been de minimis. Real Estate Loans Receivable, Net Real estate loans receivable consists of eight mezzanine loans, six term loans, and two construction loans as of March 31, 2023. Generally, each mezzanine loan is collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner, each term loan is secured by a mortgage on a related medical office building, and construction loans are secured by mortgages on the land and the improvements as constructed. The reserve for loan losses was $0.2 million as of March 31, 2023. Rental and Related Revenues Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is probable. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants are included in other assets and were approximately $102.9 million and $101.3 million as of March 31, 2023 and December 31, 2022, respectively. If the Company determines that collectability of straight-line rents is not probable, income recognition is limited to the lesser of cash collected, or lease income reflected on a straight-line basis, plus variable rent when it becomes accruable. In accordance with ASC 842, Leases, Topic 842, if the collectability of a lease changes after the commencement date, any difference between lease income that would have been recognized and the lease payments shall be recognized as an adjustment to lease income. Bad debt recognized as an adjustment to rental and related revenues was $0.4 million for the three months ended March 31, 2023 and $0.1 million for the three months ended March 31, 2022. Rental revenue is adjusted by the amortization of lease inducements and above-market or below-market rents on certain leases. Lease inducements and above-market or below-market rents are amortized on a straight-line basis over the remaining lease term. Rental and related revenues also include expense recoveries, which relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized in the period the applicable expenses are incurred. The reimbursements are recorded gross, as these costs are incurred by the Company and reimbursed by the tenants. We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses and we do not recognize expense recoveries. New Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional relief to applying reference rate reform to changing reference rates, contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (“LIBOR”), which has been discontinued at the end of 2021. The amendments in this update may be applied through December 31, 2024. The Company will continue to use published LIBOR rates through June of 2023, or until all transactions referencing LIBOR have been amended. On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Third Amended and Restated Credit Agreement to update the benchmark provisions to replace LIBOR with the Secured Overnight Financing Rate (“SOFR”), as the reference rate for the purpose of calculating interest under the agreement. In connection with amending the unsecured credit agreement, we also amended our fixed interest rate swap agreement to update reference rate from LIBOR to SOFR. As a result, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients maintains the presentation of derivatives consistent with past presentation. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
|
Investment and Disposition Activity |
3 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||
Business Combination and Asset Acquisition [Abstract] | |||||||||||||||||||||||||
Investment and Disposition Activity | Investment and Disposition ActivityDuring the three months ended March 31, 2023, the Company executed contractual commitments related to a $40.5 million development project, with quarterly costs of $1.0 million, completed the acquisition of one medical condominium unit for an investment of $1.3 million and one parcel of land adjacent to one of its medical office facilities for an investment of $0.8 million, and paid $0.3 million of additional purchase consideration under two earn-out agreements. The Company also closed on a $35.8 million construction loan, funding $4.1 million to date, and funded one term loan for $5.4 million, $1.0 million of previous construction loan commitments, and $0.5 million of previous term loan commitments. Additionally, the Company invested $0.2 million in funds managed by a real estate technology private equity fund. Investment activity totaled approximately $14.4 million during the three months ended March 31, 2023. As part of these investments, the Company incurred approximately $0.2 million of capitalized costs. The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed in connection with the acquisition of the medical condominium unit, a parcel of land adjacent to one of our medical office facilities, and two earn-out agreements, as well as follow-on capitalized costs during the three months ended March 31, 2023, which the Company determined using Level 2 and Level 3 inputs (in thousands):
Dispositions During the three months ended March 31, 2023, the Company sold one medical facility for approximately $2.6 million, realizing an insignificant gain.
|
Intangibles |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finite-Lived Intangible Assets, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangibles | Intangibles The following is a summary of the carrying amount of intangible assets and liabilities as of March 31, 2023 and December 31, 2022 (in thousands):
The following is a summary of acquired lease intangible amortization for the three months ended March 31, 2023 and 2022 (in thousands):
Future aggregate net amortization of acquired lease intangibles as of March 31, 2023, is as follows (in thousands):
|
Other Assets |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Assets, Unclassified [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Assets | Other Assets Other assets consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
|
Debt |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | Debt The following is a summary of debt as of March 31, 2023 and December 31, 2022 (in thousands):
(1)As of March 31, 2023, fixed interest mortgage notes bear interest from 3.25% to 4.63%, due in 2024, with a weighted average interest rate of 3.80%. As of December 31, 2022, fixed interest mortgage notes bear interest from 3.33% to 4.63%, due in 2024, with a weighted average interest rate of 3.85%. The notes are collateralized by two properties with a net book value of $93.1 million as of March 31, 2023 and two properties with a net book value of $94.9 million as of December 31, 2022. One mortgage bears interest at LIBOR + 1.90% and the Trust entered into a pay-fixed receive-variable interest rate swap, fixing the variable component at 1.35% as of March 31, 2023 and 1.43% as of December 31, 2022. (2)Variable interest mortgage notes bear variable interest of SOFR + 1.85% and LIBOR + 2.75% for a weighted average interest rate of 6.76% and 6.20% as of March 31, 2023 and December 31, 2022, respectively. The notes are due in 2026 and 2028 and collateralized by four properties with a net book value of $291.1 million as of March 31, 2023 and $295.5 million as of December 31, 2022. (3)The unsecured revolving credit facility bears variable interest of SOFR plus 0.95%, inclusive of a 0.10% SOFR index adjustment, as of March 31, 2023 and LIBOR plus 0.85% as of December 31, 2022. On September 24, 2021, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Third Amended and Restated Credit Agreement (the “Credit Agreement”) which extended the maturity date of the revolving credit facility under the Credit Agreement to September 24, 2025 and reduced the interest rate margin applicable to borrowings. The Credit Agreement includes an unsecured revolving credit facility of $1.0 billion and contains a term loan feature of $250.0 million, which the Company borrowed on, bringing total borrowing capacity to $1.25 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.75 billion. On October 13, 2021, the Company paid off the $250.0 million term loan feature of the Credit Agreement and the term loan feature is no longer available to the Company. The revolving credit facility under the Credit Agreement also includes two six-month extension options. Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement. On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Credit Agreement which expanded the accordion feature allowing the Operating Partnership to increase borrowing capacity by up to an additional $500.0 million, resulting in a maximum borrowing capacity of $2.25 billion, and replaced the LIBOR-based benchmark rates applicable to borrowings under the Credit Agreement with SOFR based benchmark rates plus a SOFR index adjustment of 0.10%. As of March 31, 2023, the Trust had investment grade ratings of BBB from S&P and Baa2 from Moody’s. As such, borrowings under the revolving credit facility of the Credit Agreement accrue interest on the outstanding principal at a rate of SOFR + 0.95%, inclusive of a 0.10% SOFR index adjustment. The Credit Agreement includes a facility fee equal to 0.20% per annum, which is also determined by the Trust’s investment grade rating. Base Rate Loans, Adjusted SOFR Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:
The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt, grant liens, or make distributions. The Company may, at any time, voluntarily prepay any revolving or term loan under the Credit Agreement in whole or in part without premium or penalty. As of March 31, 2023, the Company was in compliance with all financial covenants related to the Credit Agreement. The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement. As of March 31, 2023, the Company had $152.0 million of borrowings outstanding under its unsecured revolving credit facility. As defined by the Credit Agreement, the current unencumbered borrowing base allows the Company to borrow an additional $848.0 million before reaching the maximum allowed under the credit facility. Notes Payable As of March 31, 2023, the Company had $1.5 billion aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $545.0 million maturing in 2031. Certain properties have mortgage debt that contains financial covenants. As of March 31, 2023, the Trust was in compliance with all mortgage debt financial covenants. Scheduled principal payments due on consolidated debt as of March 31, 2023 are as follows (in thousands):
As of March 31, 2023, the Company had total consolidated indebtedness of approximately $1.8 billion. The weighted average interest rate on consolidated indebtedness was 4.03% (based on the 30-day LIBOR rate of 4.77% and a SOFR rate of 4.87% as of March 31, 2023). For the three months ended March 31, 2023 and 2022, the Company incurred interest expense on its debt, exclusive of deferred financing cost amortization, of $18.6 million and $16.2 million, respectively.
|
Derivatives |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instrument Detail [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivatives | Derivatives In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. As a result of the Company’s adoption of ASU 2017-12 as of January 1, 2019, the entire change in the fair value of its derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings. To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of March 31, 2023, the Company had one outstanding interest rate swap contract designated as a cash flow hedge of interest rate risk. See Note 2 (Summary of Significant Accounting Policies) of the 2022 Annual Report for a further discussion of our derivatives. In addition, the Company recognizes its share of other comprehensive income related to derivative instruments held by unconsolidated entities. The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):
(1)1.35% effective swap rate plus 1.90% spread per hedging agreement.
|
Accrued Expenses and Other Liabilities |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Liabilities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Expenses and Other Liabilities | Accrued Expenses and Other Liabilities Accrued expenses and other liabilities consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
|
Stock-based Compensation |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based Compensation | Stock-based Compensation The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances. Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available. In connection with the IPO, the Trust adopted the Physicians Realty Trust 2013 Equity Incentive Plan, which made shares available for awards for participants. On April 30, 2019, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved the Amended and Restated Physicians Realty Trust 2013 Equity Incentive Plan (“2013 Plan”). The amendment increased the number of common shares authorized for issuance under the 2013 Plan to a total of 7,000,000 common shares authorized for issuance. The 2013 Plan term was also extended to 2029. Restricted Common Shares Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. In the three months ended March 31, 2023, the Trust granted a total of 291,324 restricted common shares with a total value of $4.3 million to its officers and certain of its employees. In January 2023, under the 2013 Plan, the Company granted restricted common shares to certain of its officers under a salary deferral program, part of which vests after one year, with the remainder vesting after two years. The remaining awards have a vesting period of one year. A summary of the status of the Trust’s non-vested restricted common shares as of March 31, 2023 and changes during the three month period then ended follow:
For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the three months ended March 31, 2023 and 2022, the Company recognized non-cash share compensation of $1.1 million and $0.9 million, respectively. Unrecognized compensation expense at March 31, 2023 was $4.5 million. Restricted Share Units In January 2023, under the 2013 Plan, the Company granted 11,274 restricted share units to certain of its trustees in lieu of all or a portion of such trustee’s 2023 cash retainer. These units are subject to certain timing conditions and a one-year service period. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend. With respect to the performance and timing conditions of the January 2023 grants, the grant date fair value of $14.47 per unit was based on the share price at the date of grant. In March 2023, under the 2013 Plan, the Company granted restricted share units at a target level of 355,388 to its officers and certain of its employees and 62,586 to its trustees. Units granted to officers and certain employees under the Company’s 2013 Plan are subject to certain performance and market conditions and a three-year service period. Units granted to trustees are subject to certain timing conditions and a two-year service period for full vesting. Each restricted share unit contains one dividend equivalent. Each recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend. Approximately 30% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan in 2023 vest based on a certain market condition. The awards containing the market condition were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $18.71 per unit for the March 2023 grant using the following assumptions:
The remaining 70% of the restricted share units issued to officers and certain employees under the Company’s 2013 Plan, and 100% of other restricted share units issued to trustees vest based upon certain performance or timing conditions. With respect to the performance and timing conditions of the March 2023 grants, the grant date fair value of $14.70 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2023 restricted share units issued to officers and certain employees was $15.90 per unit. The following is a summary of the activity in the Trust’s restricted share units during the three months ended March 31, 2023:
(1)Restricted units vested by Company executives in 2023 resulted in the issuance of 652,851 common shares, less 290,380 common shares withheld to cover minimum withholding tax obligations. For the three months ended March 31, 2023 and 2022, the Company recognized non-cash share compensation of $3.5 million and $3.3 million, respectively. Unrecognized compensation expense at March 31, 2023 was $16.3 million.
|
Fair Value Measurements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value. In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. As part of the Company’s acquisition process, Level 3 inputs are used to measure the fair value of the assets acquired and liabilities assumed. The Company’s derivative instruments as of March 31, 2023 consist of one interest rate swap, as detailed in the Derivative Instruments section of Note 7 (Derivatives) of this report and Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2022 Annual Report. The interest rate swap is not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives. The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There were no such assets measured at fair value as of March 31, 2023. The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs. The following table presents the fair value of the Company’s financial instruments (in thousands):
|
Tenant Operating Leases |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Tenant Operating Leases | Tenant Operating Leases The Company is a lessor of medical office buildings and other health care facilities. Leases have expirations from 2023 through 2042. As of March 31, 2023, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and minimum rental payments for assets classified as held for sale, if applicable, were as follows (in thousands):
For the three months ended March 31, 2023 and 2022, the Company recognized $131.4 million and $127.8 million, respectively, of rental and other lease-related income related to our operating leases, of which $37.9 million and $35.1 million, respectively, were variable lease payments.
|
Rent Expense |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rent Expense | Rent Expense The Company leases the rights to parking structures at two of its properties, the air that one property occupies, and the land upon which 97 of its properties are located from third party landowners pursuant to separate leases. In addition, the Company has nine corporate leases, primarily for office space. The Company’s leases include both fixed and variable rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 93 years remaining, excluding extension options, with a weighted average remaining term of 44 years. At the inception of a new lease, the Company establishes an operating or finance lease asset and operating or finance lease liability calculated as the present value of future minimum lease payments. As our leases do not provide an implicit rate, we calculate a discount rate that approximates our incremental borrowing rate available at lease commencement to determine the present value of future minimum lease payments. The approximated weighted average discount rate was 4.4% as of March 31, 2023. There are no operating or finance leases that have not yet commenced that would have a significant impact on the Company’s consolidated balance sheets. As of March 31, 2023, the future minimum lease obligations under non-cancelable parking, air, ground, and corporate leases were as follows (in thousands):
Lease costs consisted of the following for the three months ended March 31, 2023 (in thousands):
|
Credit Concentration |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risks, Types, No Concentration Percentage [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Credit Concentration | Credit Concentration The Company uses annualized base rent (“ABR”) as its credit concentration metric. ABR is calculated by multiplying contractual base rent for the month ended March 31, 2023 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of March 31, 2023 (in thousands):
ABR collected from the Company’s top five tenant relationships comprises 19.8% of its total ABR as of March 31, 2023. Total ABR from CommonSpirit-affiliated tenants totals 14.8%, including the affiliates disclosed above. The following table summarizes certain information about the Company’s top five geographic concentrations as of March 31, 2023:
|
Earnings Per Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share | Earnings Per Share The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):
|
Subsequent Events |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events Since March 31, 2023, the Company completed the acquisition of two medical condominium units located in an Atlanta “Pill Hill” medical office building (“MOB”) for an aggregate purchase price of approximately $1.4 million and funded additional costs of $0.8 million related to our development project. The Company also contributed $2.0 million to our existing Davis Joint Venture for our pro-rata share of two earn-out agreements. Additionally, we funded a $3.4 million term loan with the Davis Joint Venture related to these earn-out agreements.
|
Summary of Significant Accounting Policies (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Noncontrolling Interests | Noncontrolling Interests The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets. Operating Partnership: Noncontrolling interests in the Company include OP Units held by other investors. Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions. As of March 31, 2023, the Trust held a 96.0% interest in the Operating Partnership. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership. Partially Owned Properties: The Trust reflects noncontrolling interests in partially owned properties on the consolidated balance sheets for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.
|
Tax Status of Dividends and Distributions | Tax Status of Dividends and Distributions The Company’s distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain. Any cash distributions received by an OP Unit holder in respect of its OP Units generally will not be taxable to such OP Unit holder for U.S. federal income tax purposes, to the extent that such distribution does not exceed the OP Unit holder’s basis in its OP Units. Any such distribution will instead reduce the OP Unit holder’s basis in its OP Units (and OP Unit holders will be subject to tax on the taxable income allocated to them by the Operating Partnership in respect of their OP Units when such income is earned by the Operating Partnership, with such income allocation increasing the OP Unit holders’ basis in their OP Units). The Company has elected taxable REIT subsidiary (“TRS”) status for certain of its corporate subsidiaries and, as a result, these entities will incur both federal and state income taxes on any taxable income of such entities after consideration of any net operating losses. To date, these income taxes have been de minimis.
|
Real Estate Loans Receivable, Net | Real Estate Loans Receivable, Net |
Rental and Related Revenues | Rental and Related Revenues Rental revenue is recognized on a straight-line basis over the terms of the related leases when collectability is probable. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due from tenants are included in other assets and were approximately $102.9 million and $101.3 million as of March 31, 2023 and December 31, 2022, respectively. If the Company determines that collectability of straight-line rents is not probable, income recognition is limited to the lesser of cash collected, or lease income reflected on a straight-line basis, plus variable rent when it becomes accruable. In accordance with ASC 842, Leases, Topic 842, if the collectability of a lease changes after the commencement date, any difference between lease income that would have been recognized and the lease payments shall be recognized as an adjustment to lease income. Bad debt recognized as an adjustment to rental and related revenues was $0.4 million for the three months ended March 31, 2023 and $0.1 million for the three months ended March 31, 2022. Rental revenue is adjusted by the amortization of lease inducements and above-market or below-market rents on certain leases. Lease inducements and above-market or below-market rents are amortized on a straight-line basis over the remaining lease term. Rental and related revenues also include expense recoveries, which relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized in the period the applicable expenses are incurred. The reimbursements are recorded gross, as these costs are incurred by the Company and reimbursed by the tenants. We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses and we do not recognize expense recoveries.
|
New Accounting Pronouncements | New Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional relief to applying reference rate reform to changing reference rates, contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (“LIBOR”), which has been discontinued at the end of 2021. The amendments in this update may be applied through December 31, 2024. The Company will continue to use published LIBOR rates through June of 2023, or until all transactions referencing LIBOR have been amended. On March 31, 2023, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a First Amendment to the Third Amended and Restated Credit Agreement to update the benchmark provisions to replace LIBOR with the Secured Overnight Financing Rate (“SOFR”), as the reference rate for the purpose of calculating interest under the agreement. In connection with amending the unsecured credit agreement, we also amended our fixed interest rate swap agreement to update reference rate from LIBOR to SOFR. As a result, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients maintains the presentation of derivatives consistent with past presentation. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
|
Derivatives | In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception. When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. As a result of the Company’s adoption of ASU 2017-12 as of January 1, 2019, the entire change in the fair value of its derivatives designated and qualified as cash flow hedges are recorded in accumulated other comprehensive income on the consolidated balance sheets and are subsequently reclassified into earnings in the period in which the hedged forecasted transaction affects earnings. To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of March 31, 2023, the Company had one outstanding interest rate swap contract designated as a cash flow hedge of interest rate risk. See Note 2 (Summary of Significant Accounting Policies) of the 2022 Annual Report for a further discussion of our derivatives. In addition, the Company recognizes its share of other comprehensive income related to derivative instruments held by unconsolidated entities.
|
Fair Value Measurements | The Company’s derivative instruments as of March 31, 2023 consist of one interest rate swap, as detailed in the Derivative Instruments section of Note 7 (Derivatives) of this report and Note 2 (Summary of Significant Accounting Policies) of Part II, Item 8 (Financial Statements and Supplementary Data) of our 2022 Annual Report. The interest rate swap is not traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives. The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There were no such assets measured at fair value as of March 31, 2023. The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.
|
Stock-based Compensation | The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances. Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available.
|
Investment and Disposition Activity (Tables) |
3 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||
Business Combination and Asset Acquisition [Abstract] | |||||||||||||||||||||||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The following table summarizes the acquisition date fair values of the assets acquired and the liabilities assumed in connection with the acquisition of the medical condominium unit, a parcel of land adjacent to one of our medical office facilities, and two earn-out agreements, as well as follow-on capitalized costs during the three months ended March 31, 2023, which the Company determined using Level 2 and Level 3 inputs (in thousands):
|
Intangibles (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finite-Lived Intangible Assets, Net [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the carrying amount of intangible assets and liabilities | The following is a summary of the carrying amount of intangible assets and liabilities as of March 31, 2023 and December 31, 2022 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the carrying amount of acquired lease intangibles | The following is a summary of acquired lease intangible amortization for the three months ended March 31, 2023 and 2022 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of future amortization of the acquired lease intangibles | Future aggregate net amortization of acquired lease intangibles as of March 31, 2023, is as follows (in thousands):
|
Other Assets (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Assets, Unclassified [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of other assets | Other assets consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
|
Debt (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of debt | The following is a summary of debt as of March 31, 2023 and December 31, 2022 (in thousands):
(1)As of March 31, 2023, fixed interest mortgage notes bear interest from 3.25% to 4.63%, due in 2024, with a weighted average interest rate of 3.80%. As of December 31, 2022, fixed interest mortgage notes bear interest from 3.33% to 4.63%, due in 2024, with a weighted average interest rate of 3.85%. The notes are collateralized by two properties with a net book value of $93.1 million as of March 31, 2023 and two properties with a net book value of $94.9 million as of December 31, 2022. One mortgage bears interest at LIBOR + 1.90% and the Trust entered into a pay-fixed receive-variable interest rate swap, fixing the variable component at 1.35% as of March 31, 2023 and 1.43% as of December 31, 2022. (2)Variable interest mortgage notes bear variable interest of SOFR + 1.85% and LIBOR + 2.75% for a weighted average interest rate of 6.76% and 6.20% as of March 31, 2023 and December 31, 2022, respectively. The notes are due in 2026 and 2028 and collateralized by four properties with a net book value of $291.1 million as of March 31, 2023 and $295.5 million as of December 31, 2022. (3)The unsecured revolving credit facility bears variable interest of SOFR plus 0.95%, inclusive of a 0.10% SOFR index adjustment, as of March 31, 2023 and LIBOR plus 0.85% as of December 31, 2022.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of adjusted LIBOR rate loans and interest rates based on credit rating | Base Rate Loans, Adjusted SOFR Loans, and Letters of Credit (each, as defined in the Credit Agreement) will be subject to interest rates, based upon the Trust’s investment grade rating as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of principal payments due on debt | Scheduled principal payments due on consolidated debt as of March 31, 2023 are as follows (in thousands):
|
Derivatives (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instrument Detail [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of interest rate derivatives | The following table summarizes the location and aggregate fair value of the interest rate swaps on the Company’s consolidated balance sheets (in thousands):
(1)1.35% effective swap rate plus 1.90% spread per hedging agreement.
|
Accrued Expenses and Other Liabilities (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Liabilities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of accrued expenses and other liabilities | Accrued expenses and other liabilities consisted of the following as of March 31, 2023 and December 31, 2022 (in thousands):
|
Stock-based Compensation (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of non-vested restricted common shares | A summary of the status of the Trust’s non-vested restricted common shares as of March 31, 2023 and changes during the three month period then ended follow:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of weighted average grant date fair value assumptions | The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $18.71 per unit for the March 2023 grant using the following assumptions:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the activity in the restricted share units | The following is a summary of the activity in the Trust’s restricted share units during the three months ended March 31, 2023:
(1)Restricted units vested by Company executives in 2023 resulted in the issuance of 652,851 common shares, less 290,380 common shares withheld to cover minimum withholding tax obligations.
|
Fair Value Measurements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of fair value of other financial instruments | The following table presents the fair value of the Company’s financial instruments (in thousands):
|
Tenant Operating Leases (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||
Lessor, operating lease, payments to be received, maturity | As of March 31, 2023, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries and minimum rental payments for assets classified as held for sale, if applicable, were as follows (in thousands):
|
Rent Expense (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of future minimum lease obligations under non-cancelable ground leases | As of March 31, 2023, the future minimum lease obligations under non-cancelable parking, air, ground, and corporate leases were as follows (in thousands):
|
Credit Concentration (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration Risks, Types, No Concentration Percentage [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedules of concentration of risk, by risk factor | The following table summarizes certain information about the Company’s top five tenant credit concentrations as of March 31, 2023 (in thousands):
The following table summarizes certain information about the Company’s top five geographic concentrations as of March 31, 2023:
|
Earnings Per Share (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of amounts used in computing basic and diluted earnings per share | The following table shows the amounts used in computing the Trust’s basic and diluted earnings per share (in thousands, except share and per share data):
|
Organization and Business - Additional Information (Details) - $ / shares |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Common stock, shares authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Organization and Business - ATM Program (Details) - Private Placement - ATM Program - USD ($) |
1 Months Ended | 3 Months Ended |
---|---|---|
May 31, 2021 |
Mar. 31, 2023 |
|
Maximum | ||
Class of Stock [Line Items] | ||
Aggregate offering price of common stock | $ 500,000,000 | |
Operating Partnership | ||
Class of Stock [Line Items] | ||
Common shares sold (in shares) | 4,400,000 | |
Weighted average price (in dollars per share) | $ 15.10 | |
Proceeds from issuance of common stock | $ 65,800,000 | |
Sale of stock, remaining authorized amount | $ 158,600,000 |
Summary of Significant Accounting Policies - Noncontrolling Interests and Redeemable Noncontrolling Interests (Details) |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
Physicians Realty Trust | |
Business Acquisition [Line Items] | |
Percentage of interest held | 96.00% |
Summary of Significant Accounting Policies - Dividends and Distributions (Details) - $ / shares |
3 Months Ended | ||
---|---|---|---|
Mar. 17, 2023 |
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Accounting Policies [Abstract] | |||
Dividends and distributions declared per common share and OP Unit (in dollars per share) | $ 0.23 | $ 0.23 | $ 0.23 |
Summary of Significant Accounting Policies - Real Estate Loans Receivable, Net (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2023
USD ($)
loan
| |
Property, Plant and Equipment [Line Items] | |
Financing receivable, allowance for credit loss | $ | $ 0.2 |
Mezzanine Loan Receivable | |
Property, Plant and Equipment [Line Items] | |
Number of mezzanine loans collateralized | 8 |
Term Loan Receivable | |
Property, Plant and Equipment [Line Items] | |
Number of mezzanine loans collateralized | 6 |
Construction Loans | |
Property, Plant and Equipment [Line Items] | |
Number of mezzanine loans collateralized | 2 |
Summary of Significant Accounting Policies - Rental and Related Revenues (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
Dec. 31, 2022 |
|
Accounting Policies [Abstract] | |||
Straight line rent receivable, net | $ 102,856 | $ 101,306 | |
Operating lease, bad debt expense | $ 400 | $ 100 |
Investment and Disposition Activity - Narrative (Details) $ in Millions |
3 Months Ended |
---|---|
Mar. 31, 2023
USD ($)
earn-outAgreement
condominiumUnit
medicalFacility
land
loan
| |
Asset Acquisition [Line Items] | |
Contractual obligation | $ 40.5 |
Contractual obligation, quarterly payment amount | 1.0 |
Payments to acquire real estate, payments for loans receivable and payments for real estate investments | 14.4 |
Asset acquisition, capitalized costs | $ 0.2 |
Disposal Group, Held-for-sale, Not Discontinued Operations | |
Asset Acquisition [Line Items] | |
Number of real estate properties sold | medicalFacility | 1 |
Proceeds from divestiture of businesses | $ 2.6 |
One Medical Condominium Unit Acquired in 2023 | |
Asset Acquisition [Line Items] | |
Number of medical condominium units | condominiumUnit | 1 |
Asset acquisition, consideration transferred | $ 1.3 |
One Parcel Of Land Acquired 2023 | |
Asset Acquisition [Line Items] | |
Asset acquisition, consideration transferred | $ 0.8 |
Number of land parcels acquired | land | 1 |
Earn-Out Investments | |
Asset Acquisition [Line Items] | |
Asset acquisition, consideration transferred | $ 0.3 |
Number of earn-out agreements | earn-outAgreement | 2 |
Construction Loans | |
Asset Acquisition [Line Items] | |
Construction loan | $ 35.8 |
Payments for (proceeds from) loans receivable | 4.1 |
Term Loan | |
Asset Acquisition [Line Items] | |
Payments for (proceeds from) loans receivable | $ 5.4 |
Number of mezzanine loans collateralized | loan | 1 |
Previous Construction Loan | |
Asset Acquisition [Line Items] | |
Payments for (proceeds from) loans receivable | $ 1.0 |
Previous Term Loan | |
Asset Acquisition [Line Items] | |
Payments for (proceeds from) loans receivable | 0.5 |
Private Equity Funds | |
Asset Acquisition [Line Items] | |
Payments to acquire investments | $ 0.2 |
Investment and Disposition Activity - Summary of Acquisition Date Fair Values (Details) $ in Thousands |
Mar. 31, 2023
USD ($)
|
---|---|
Business Combination and Asset Acquisition [Abstract] | |
Land | $ 1,356 |
Building and improvements | 1,294 |
Cash used in acquisition of investment property | $ 2,650 |
Intangibles - Summary of Carrying Amount of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Liabilities | ||
Below-market leases, net | $ 23,796 | $ 24,381 |
In-place leases | ||
Assets: | ||
Cost | 445,322 | 445,583 |
Accumulated Amortization | (251,995) | (241,643) |
Net | 193,327 | 203,940 |
Above-market leases | ||
Assets: | ||
Cost | 59,752 | 59,752 |
Accumulated Amortization | (31,511) | (30,096) |
Net | 28,241 | 29,656 |
Below-market leases | ||
Liabilities | ||
Below-market leases, cost | 36,409 | 37,002 |
Below-market leases, accumulated amortization | (12,613) | (12,621) |
Below-market leases, net | $ 23,796 | $ 24,381 |
Intangibles - Summary of Acquired Amortization (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Amortization expense related to in-place leases | ||
Intangibles | ||
Amortization expense related to in-place leases | $ 10,612 | $ 11,040 |
Decrease in rental income related to above-market leases | ||
Intangibles | ||
Decrease of rental income | 1,415 | 1,502 |
Below market in-place lease intangibles | ||
Intangibles | ||
Increase in rental income related to below-market leases | $ 586 | $ 459 |
Intangibles - Additional Information (Details) |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
In-place lease intangibles | |
Intangibles | |
Weighted average amortization period for lease intangibles | 7 years |
Above-market leases | |
Intangibles | |
Weighted average amortization period for lease intangibles | 7 years |
Leasehold Interest | |
Intangibles | |
Weighted average amortization period for lease intangibles | 7 years |
Below market in-place lease intangibles | |
Intangibles | |
Weighted average amortization period for lease intangibles | 15 years |
Intangibles - Future Aggregate Net Amortization of Acquired Lease Intangibles (Details) $ in Thousands |
Mar. 31, 2023
USD ($)
|
---|---|
Net Decrease (Increase) in Revenue | |
2023 | $ 2,361 |
2024 | 2,929 |
2025 | 2,357 |
2026 | 1,203 |
2027 | 1,036 |
Thereafter | (5,441) |
Total | 4,445 |
Net Increase in Expenses | |
2023 | 30,004 |
2024 | 34,718 |
2025 | 29,208 |
2026 | 23,095 |
2027 | 20,173 |
Thereafter | 56,129 |
Total | $ 193,327 |
Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Other Assets, Unclassified [Abstract] | ||
Straight line rent receivable, net | $ 102,856 | $ 101,306 |
Prepaid expenses | 10,657 | 11,009 |
Leasing commissions, net | 13,449 | 13,231 |
Lease inducements, net | 8,065 | 7,894 |
Interest rate swap | 1,645 | 2,045 |
Escrows | 1,352 | 1,565 |
Notes receivable, net | 367 | 370 |
Other | 8,659 | 9,387 |
Total | $ 147,050 | $ 146,807 |
Debt - Summary of Debt (Details) |
3 Months Ended | 12 Months Ended | |
---|---|---|---|
Mar. 31, 2023
USD ($)
healthcareproperty
|
Dec. 31, 2022
USD ($)
healthcareproperty
|
Sep. 24, 2021
USD ($)
|
|
Debt | |||
Long-term debt, gross | $ 1,776,676,000 | $ 1,832,929,000 | |
Unamortized deferred financing costs | (6,899,000) | (7,453,000) | |
Unamortized discounts | (7,087,000) | (7,359,000) | |
Total debt | 1,762,690,000 | 1,818,117,000 | |
2021 Third Amended and Restated Credit Agreement | |||
Debt | |||
Current borrowing capacity | $ 1,250,000,000 | ||
Mortgages | |||
Debt | |||
Long-term debt, gross | 164,676,000 | 164,929,000 | |
Mortgages | Fixed rate mortgage | |||
Debt | |||
Long-term debt, gross | $ 59,641,000 | $ 59,776,000 | |
Weighted average interest rate | 3.80% | 3.85% | |
Pledged assets separately reported real estate pledged as collateral number | healthcareproperty | 2 | 2 | |
Mortgages | Fixed rate mortgage | Asset Pledged as Collateral | |||
Debt | |||
Financial instruments, owned, at fair value | $ 93,100,000 | $ 94,900,000 | |
Mortgages | Fixed rate mortgage | Minimum | |||
Debt | |||
Interest rate (as a percent) | 3.25% | 3.33% | |
Mortgages | Fixed rate mortgage | Maximum | |||
Debt | |||
Interest rate (as a percent) | 4.63% | 4.63% | |
Mortgages | Variable interest mortgage note | |||
Debt | |||
Long-term debt, gross | $ 105,035,000 | $ 105,153,000 | |
Weighted average interest rate | 6.76% | 6.20% | |
Pledged assets separately reported real estate pledged as collateral number | healthcareproperty | 4 | ||
Mortgages | Variable interest mortgage note | Asset Pledged as Collateral | |||
Debt | |||
Financial instruments, owned, at fair value | $ 291,100,000 | $ 295,500,000 | |
Mortgages | Variable interest mortgage note | London Interbank Offered Rate (LIBOR) | |||
Debt | |||
Reference rate (as a percent) | 2.75% | ||
Mortgages | Variable interest mortgage note | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Maximum | |||
Debt | |||
Reference rate (as a percent) | 1.85% | ||
Revolving credit facility | |||
Debt | |||
Current borrowing capacity | $ 848,000,000 | ||
Revolving credit facility | $1.0 billion unsecured revolving credit facility due September 2025 | |||
Debt | |||
Long-term debt, gross | 152,000,000 | $ 193,000,000 | |
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | |||
Debt | |||
Current borrowing capacity | $ 1,000,000,000 | $ 1,000,000,000 | |
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | London Interbank Offered Rate (LIBOR) | |||
Debt | |||
Reference rate (as a percent) | 0.85% | ||
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |||
Debt | |||
Reference rate (as a percent) | 0.95% | ||
Debt instrument, variable rate, index adjustment | 0.10% | ||
Senior notes | |||
Debt | |||
Total debt | $ 1,500,000,000 | ||
Senior notes | $400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027 | |||
Debt | |||
Long-term debt, gross | 400,000,000 | $ 400,000,000 | |
Debt instrument, face amount | $ 400,000,000 | ||
Interest rate (as a percent) | 4.30% | ||
Senior notes | $350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028 | |||
Debt | |||
Long-term debt, gross | $ 350,000,000 | 350,000,000 | |
Debt instrument, face amount | $ 350,000,000 | ||
Interest rate (as a percent) | 3.95% | ||
Senior notes | $500 million senior unsecured notes bearing fixed interest of 2.625%, due November 2031 | |||
Debt | |||
Long-term debt, gross | $ 500,000,000 | 500,000,000 | |
Debt instrument, face amount | $ 500,000,000 | ||
Interest rate (as a percent) | 2.625% | ||
Senior notes | $135 million senior unsecured notes bearing fixed interest of 4.43% to 4.74%, due January 2026 to 2031 | |||
Debt | |||
Long-term debt, gross | $ 135,000,000 | 150,000,000 | |
Debt instrument, face amount | $ 135,000,000 | ||
Senior notes | $135 million senior unsecured notes bearing fixed interest of 4.43% to 4.74%, due January 2026 to 2031 | Minimum | |||
Debt | |||
Interest rate (as a percent) | 4.43% | ||
Senior notes | $135 million senior unsecured notes bearing fixed interest of 4.43% to 4.74%, due January 2026 to 2031 | Maximum | |||
Debt | |||
Interest rate (as a percent) | 4.74% | ||
Senior notes | $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | |||
Debt | |||
Long-term debt, gross | $ 75,000,000 | $ 75,000,000 | |
Debt instrument, face amount | $ 75,000,000 | ||
Senior notes | $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | Minimum | |||
Debt | |||
Interest rate (as a percent) | 4.09% | ||
Senior notes | $75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | Maximum | |||
Debt | |||
Interest rate (as a percent) | 4.24% | ||
Unsecured Debt | Derivative assets | |||
Debt | |||
Effective fixed interest rate (as a percent) | 1.35% | 1.43% | |
Unsecured Debt | 2018 Credit Agreement Amendment | |||
Debt | |||
Reference rate (as a percent) | 1.90% |
Debt - Additional Information (Details) |
3 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Mar. 31, 2023
USD ($)
extensionOption
|
Mar. 31, 2022
USD ($)
|
Dec. 31, 2022
USD ($)
|
Oct. 13, 2021
USD ($)
|
Sep. 24, 2021
USD ($)
|
|
Debt | |||||
Long-term debt | $ 1,762,690,000 | $ 1,818,117,000 | |||
Long-term debt, gross | 1,776,676,000 | $ 1,832,929,000 | |||
Interest expense, debt | 18,600,000 | $ 16,200,000 | |||
2021 Third Amended and Restated Credit Agreement | |||||
Debt | |||||
Current borrowing capacity | $ 1,250,000,000 | ||||
Maximum borrowing capacity as a percentage of maximum principal amount | 10.00% | ||||
Accordion feature, increase limit | $ 500,000,000 | ||||
Maximum borrowing capacity under accordion feature | 1,750,000,000 | ||||
2023 First Amendment To The Third Amended And Restated Credit Agreement | |||||
Debt | |||||
Accordion feature, increase limit | 500,000,000 | ||||
Maximum borrowing capacity under accordion feature | $ 2,250,000,000 | ||||
Unused fee (as a percent) | 0.20% | ||||
2023 First Amendment To The Third Amended And Restated Credit Agreement | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |||||
Debt | |||||
Reference rate (as a percent) | 0.95% | ||||
Revolving credit facility | |||||
Debt | |||||
Current borrowing capacity | $ 848,000,000 | ||||
Number of extension options | extensionOption | 2 | ||||
Term of extension option | 6 months | ||||
Amount outstanding | $ 152,000,000 | ||||
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | |||||
Debt | |||||
Current borrowing capacity | $ 1,000,000,000 | 1,000,000,000 | |||
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | London Interbank Offered Rate (LIBOR) | |||||
Debt | |||||
Reference rate (as a percent) | 0.85% | ||||
Revolving credit facility | 2021 Third Amended and Restated Credit Agreement | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |||||
Debt | |||||
Debt instrument, variable rate, index adjustment | 0.10% | ||||
Reference rate (as a percent) | 0.95% | ||||
Term Loan | |||||
Debt | |||||
Amount outstanding | $ 250,000,000 | ||||
Term Loan | 2021 Third Amended and Restated Credit Agreement | |||||
Debt | |||||
Current borrowing capacity | $ 250,000,000 | ||||
Senior notes | |||||
Debt | |||||
Long-term debt | $ 1,500,000,000 | ||||
Senior notes | Senior Notes Due 2025 | |||||
Debt | |||||
Long-term debt | 25,000,000 | ||||
Senior notes | Senior Notes Due 2026 | |||||
Debt | |||||
Long-term debt | 70,000,000 | ||||
Senior notes | Senior Notes Due 2027 | |||||
Debt | |||||
Long-term debt | 425,000,000 | ||||
Senior notes | Senior Notes Due 2028 | |||||
Debt | |||||
Long-term debt | 395,000,000 | ||||
Senior notes | Senior Notes Due 2031 | |||||
Debt | |||||
Long-term debt | $ 545,000,000 | ||||
Operating Partnership | Revolving credit facility | |||||
Debt | |||||
Interest rate at end of period (as a percent) | 4.03% | ||||
Operating Partnership | Revolving credit facility | London Interbank Offered Rate (LIBOR) | |||||
Debt | |||||
Reference rate (as a percent) | 4.77% | ||||
Operating Partnership | Revolving credit facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |||||
Debt | |||||
Reference rate (as a percent) | 4.87% |
Debt - Trust Investment Grade Rating (Details) |
3 Months Ended |
---|---|
Mar. 31, 2023 | |
At Least A- or A3 | Adjusted SOFR rate loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 0.725% |
At Least A- or A3 | Adjusted SOFR rate term loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 0.85% |
At Least BBB+ or Baa1 | Adjusted SOFR rate loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 0.775% |
At Least BBB+ or Baa1 | Adjusted SOFR rate term loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 0.90% |
At Least BBB or Baa2 | Adjusted SOFR rate loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 0.85% |
At Least BBB or Baa2 | Adjusted SOFR rate term loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 1.00% |
At Least BBB- or Baa3 | Adjusted SOFR rate loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 1.05% |
At Least BBB- or Baa3 | Adjusted SOFR rate term loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 1.25% |
Below BBB- or Baa3 | Adjusted SOFR rate loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 1.40% |
Below BBB- or Baa3 | Adjusted SOFR rate term loans and letter of credit | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | |
Debt | |
Reference rate (as a percent) | 1.65% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least A- or A3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least BBB+ or Baa1 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least BBB or Baa2 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Revolving Loans: Base Rate Loans | At Least BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.05% |
Applicable Margin for Revolving Loans: Base Rate Loans | Below BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.40% |
Applicable Margin for Term Loans: Base Rate Loans | At Least A- or A3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Term Loans: Base Rate Loans | At Least BBB+ or Baa1 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Term Loans: Base Rate Loans | At Least BBB or Baa2 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.00% |
Applicable Margin for Term Loans: Base Rate Loans | At Least BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.25% |
Applicable Margin for Term Loans: Base Rate Loans | Below BBB- or Baa3 | Base rate loans | Base rate | |
Debt | |
Reference rate (as a percent) | 0.65% |
Debt - Scheduled Principal Payments (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Debt Disclosure [Abstract] | ||
2023 | $ 754 | |
2024 | 59,719 | |
2025 | 177,476 | |
2026 | 170,476 | |
2027 | 425,476 | |
Thereafter | 942,775 | |
Total Payments | $ 1,776,676 | $ 1,832,929 |
Derivatives - Additional Information (Details) |
Mar. 31, 2023
instrument
|
---|---|
Derivative assets | |
Derivative [Line Items] | |
Outstanding interest rate swap contracts designated as cash flow hedges | 1 |
Derivatives - Location and Aggregate Fair Value of Interest Rate Swaps (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Dec. 31, 2022 |
|
Derivative [Line Items] | ||
Total notional amount | $ 36,050,000 | |
Effective date | Oct. 31, 2019 | |
Maturity date | Oct. 31, 2024 | |
Derivative assets | Carrying Amount | ||
Derivative [Line Items] | ||
Asset balance at March 31, 2023 (included in Other assets) | $ 1,645,000 | $ 2,045,000 |
Asset balance at December 31, 2022 (included in Other assets) | $ 2,045,000 | |
Unsecured Debt | 2018 Credit Agreement Amendment | ||
Derivative [Line Items] | ||
Reference rate (as a percent) | 1.90% | |
Unsecured Debt | Derivative assets | ||
Derivative [Line Items] | ||
Effective fixed interest rate | 3.25% | |
Effective fixed interest rate (as a percent) | 1.35% | 1.43% |
Accrued Expenses and Other Liabilities - Schedule of Accrued Expense and Other Liabilities (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Other Liabilities Disclosure [Abstract] | ||
Real estate taxes payable | $ 18,982 | $ 23,303 |
Prepaid rent | 29,041 | 21,062 |
Accrued interest | 11,540 | 18,196 |
Accrued expenses | 8,524 | 7,920 |
Accrued incentive compensation | 1,579 | 2,700 |
Security deposits | 4,382 | 4,338 |
Tenant improvement allowances | 1,401 | 1,831 |
Other | 9,558 | 8,370 |
Total | $ 85,007 | $ 87,720 |
Stock-based Compensation - Additional Information (Details) |
Apr. 30, 2019
shares
|
---|---|
Restricted common shares | 2013 Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Maximum number of shares authorized (in shares) | 7,000,000 |
Stock-based Compensation - Restricted Common Shares (Narrative) (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | |
---|---|---|---|
Jan. 31, 2023 |
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Non-cash share compensation | $ 4,667 | $ 4,253 | |
2013 Plan | Restricted common shares | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Granted (in shares) | 291,324 | ||
Non-cash share compensation | $ 1,100 | $ 900 | |
Unrecognized compensation expense | $ 4,500 | ||
2013 Plan | Restricted common shares | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 1 year | ||
Equity Incentive Plan 2023 | Restricted common shares | Maximum | Share-based Payment Arrangement, Tranche One | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 1 year | ||
Equity Incentive Plan 2023 | Restricted common shares | Maximum | Share-based Payment Arrangement, Tranche Two | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Vesting period | 2 years | ||
Officers and Certain Employees | 2013 Plan | Restricted common shares | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Granted (in shares) | 291,324 | ||
Grant date value | $ 4,300 |
Stock-based Compensation - Summary of the Status of the Trust's Non-Vested Restricted Common Shares (Details) - 2013 Plan - Restricted common shares |
3 Months Ended |
---|---|
Mar. 31, 2023
$ / shares
shares
| |
Common Shares | |
Non-vested at the beginning of the period (in shares) | shares | 272,898 |
Granted (in shares) | shares | 291,324 |
Vested (in shares) | shares | (210,380) |
Forfeited (in shares) | shares | (364) |
Non-vested at the end of the period (in shares) | shares | 353,478 |
Weighted Average Grant Date Fair Value | |
Non-vested at beginning of period (in dollars per share) | $ / shares | $ 16.69 |
Granted (in dollars per share) | $ / shares | 14.67 |
Vested (in dollars per share) | $ / shares | 16.37 |
Forfeited (in dollars per share) | $ / shares | 17.45 |
Non-vested at end of period (in dollars per share) | $ / shares | $ 15.21 |
Stock-based Compensation - Restricted Share Units (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2023 |
Jan. 31, 2023 |
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Non-cash share compensation | $ 4,667 | $ 4,253 | ||
2013 Plan | Restricted share units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of dividend equivalent included in each award (in shares) | 1 | 1 | ||
Non-cash share compensation | $ 3,500 | $ 3,300 | ||
Unrecognized compensation expense | $ 16,300 | $ 16,300 | ||
2013 Plan | Performance based restricted stock units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Performance conditions grant date fair value (in dollars per share) | $ 14.70 | |||
Granted (in dollars per share) | 15.90 | |||
2013 Plan | Market Based Restricted Stock Units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in dollars per share) | $ 18.71 | |||
Officers and Certain Employees | 2013 Plan | Restricted share units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 355,388 | |||
Vesting period | 3 years | 1 year | ||
Officers and Certain Employees | 2013 Plan | Performance based restricted stock units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting percentage | 70.00% | |||
Officers and Certain Employees | 2013 Plan | Market Based Restricted Stock Units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting percentage | 30.00% | |||
Trustees | 2013 Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 11,274 | |||
Trustees | 2013 Plan | Restricted share units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Granted (in shares) | 62,586 | |||
Vesting period | 2 years | |||
Number of dividend equivalent included in each award (in shares) | 1 | |||
Trustees | 2013 Plan | Performance based restricted stock units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Performance conditions grant date fair value (in dollars per share) | $ 14.47 | |||
Percentage of restricted share units issued to trustees | 100.00% |
Stock-based Compensation - Restricted Share Assumptions (Details) - 2013 Plan - Restricted share units (RSUs) |
1 Months Ended |
---|---|
Mar. 31, 2023
$ / shares
| |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Volatility | 23.40% |
Expected term in years | 2 years 9 months 29 days |
Risk-free rate | 4.70% |
Share price (per share) | $ 14.70 |
Stock-based Compensation - Summary of Activity in the Trust's Restricted Share Units (Details) |
3 Months Ended | |
---|---|---|
Mar. 31, 2023
$ / shares
shares
|
Dec. 31, 2022
shares
|
|
Weighted Average Grant Date Fair Value | ||
Common stock, shares issued (in shares) | 238,395,869 | 233,292,030 |
2013 Plan | Executive Awards | ||
Restricted Share Units | ||
Non-vested at the beginning of the period (in shares) | 1,046,940 | |
Granted (in shares) | 355,388 | |
Vested (in shares) | (223,579) | |
Non-vested at the end of the period (in shares) | 1,178,749 | |
Weighted Average Grant Date Fair Value | ||
Non-vested at beginning of period (in dollars per share) | $ / shares | $ 21.41 | |
Granted (in dollars per share) | $ / shares | 15.90 | |
Vested (in dollars per share) | $ / shares | 24.36 | |
Non-vested at end of period (in dollars per share) | $ / shares | $ 19.19 | |
Common stock, shares issued (in shares) | 652,851 | |
Restricted stock, shares issued net of shares for tax withholdings (in shares) | 290,380 | |
2013 Plan | Trustee Awards | ||
Restricted Share Units | ||
Non-vested at the beginning of the period (in shares) | 77,992 | |
Granted (in shares) | 73,860 | |
Vested (in shares) | (49,890) | |
Non-vested at the end of the period (in shares) | 101,962 | |
Weighted Average Grant Date Fair Value | ||
Non-vested at beginning of period (in dollars per share) | $ / shares | $ 16.60 | |
Granted (in dollars per share) | $ / shares | 14.66 | |
Vested (in dollars per share) | $ / shares | 16.74 | |
Non-vested at end of period (in dollars per share) | $ / shares | $ 15.13 |
Fair Value Measurements - Additional Information (Details) |
Mar. 31, 2023
instrument
asset
|
---|---|
Fair value, measurements, nonrecurring | |
Fair value of other financial instruments | |
Number of assets measured at fair value | asset | 0 |
Derivative assets | |
Fair value of other financial instruments | |
Outstanding interest rate swap contracts designated as cash flow hedges | instrument | 1 |
Fair Value Measurements - Fair Value of Company's Financial Instruments (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Assets: | ||
Notes receivable, net | $ 367 | $ 370 |
Liabilities: | ||
Credit facility | (147,762) | (188,328) |
Notes payable | (1,450,798) | (1,465,437) |
Mortgage debt | (164,130) | (164,352) |
Carrying Amount | ||
Assets: | ||
Real estate loans receivable, net | 115,764 | 104,973 |
Notes receivable, net | 367 | 370 |
Liabilities: | ||
Credit facility | (152,000) | (193,000) |
Notes payable | (1,460,000) | (1,475,000) |
Mortgage debt | (164,676) | (164,929) |
Carrying Amount | Derivative assets | ||
Assets: | ||
Asset balance at March 31, 2023 (included in Other assets) | 1,645 | 2,045 |
Liabilities: | ||
Derivative liabilities | (2,045) | |
Fair Value | ||
Assets: | ||
Real estate loans receivable, net | 113,453 | 102,162 |
Notes receivable, net | 367 | 370 |
Liabilities: | ||
Credit facility | (152,000) | (193,000) |
Notes payable | (1,307,272) | (1,302,767) |
Mortgage debt | (163,429) | (163,129) |
Fair Value | Derivative assets | ||
Assets: | ||
Asset balance at March 31, 2023 (included in Other assets) | $ 1,645 | $ 2,045 |
Tenant Operating Leases - Schedule of Future Minimum Rental Payments (Details) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
Leases [Abstract] | ||
2023 | $ 270,431 | |
2024 | 352,374 | |
2025 | 334,894 | |
2026 | 278,001 | |
2027 | 226,004 | |
Thereafter | 764,694 | |
Total | 2,226,398 | |
Operating lease, lease income | 131,400 | $ 127,800 |
Operating lease, variable lease income | $ 37,900 | $ 35,100 |
Rent Expense - Additional Information (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2023
USD ($)
property
lease
| |
Leases [Abstract] | |
Number of properties subject to parking lease | 2 |
Number of properties subject to air space lease | 1 |
Number of properties subject to ground leases | 97 |
Number of office space leases | lease | 9 |
Maximum lease terms | 93 years |
Operating lease, weighted average remaining lease term | 44 years |
Operating lease, weighted average discount rate, percent | 4.40% |
Fixed lease cost | $ | $ 817 |
Rent Expense - Schedule of Future Minimum Lease Obligations (Details) - USD ($) $ in Thousands |
Mar. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Leases [Abstract] | ||
2023 | $ 3,539 | |
2024 | 4,819 | |
2025 | 4,798 | |
2026 | 4,787 | |
2027 | 4,789 | |
Thereafter | 239,130 | |
Total undiscounted lease payments | 261,862 | |
Less: Interest | (157,006) | |
Present value of lease liabilities | $ 104,856 | $ 105,011 |
Rent Expense - Lease Cost (Details) $ in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2023
USD ($)
| |
Leases [Abstract] | |
Fixed lease cost | $ 817 |
Variable lease cost | 338 |
Total lease cost | $ 1,155 |
Credit Concentration - Schedule of ABR (Annualized Base Rent) (Details) - Sales Revenue, Services, Net |
3 Months Ended |
---|---|
Mar. 31, 2023
USD ($)
Rate
| |
Customer Concentration Risk | |
Concentration Risk [Line Items] | |
Total ABR | $ 360,974,000 |
Percent of ABR | Rate | 100.00% |
Customer Concentration Risk | CommonSpirit - CHI - Nebraska | |
Concentration Risk [Line Items] | |
Total ABR | $ 18,142,000 |
Percent of ABR | Rate | 5.00% |
Customer Concentration Risk | Northside Hospital | |
Concentration Risk [Line Items] | |
Total ABR | $ 16,238,000 |
Percent of ABR | Rate | 4.50% |
Customer Concentration Risk | UofL Health - Louisville, Inc. | |
Concentration Risk [Line Items] | |
Total ABR | $ 14,373,000 |
Percent of ABR | Rate | 4.00% |
Customer Concentration Risk | US Oncology | |
Concentration Risk [Line Items] | |
Total ABR | $ 11,443,000 |
Percent of ABR | Rate | 3.20% |
Customer Concentration Risk | HonorHealth | |
Concentration Risk [Line Items] | |
Total ABR | $ 11,220,000 |
Percent of ABR | Rate | 3.10% |
Customer Concentration Risk | Remaining portfolio | |
Concentration Risk [Line Items] | |
Total ABR | $ 289,558,000 |
Percent of ABR | Rate | 80.20% |
Geographic Concentration Risk | |
Concentration Risk [Line Items] | |
Total ABR | $ 360,974,000 |
Percent of ABR | Rate | 100.00% |
Geographic Concentration Risk | Texas | |
Concentration Risk [Line Items] | |
Total ABR | $ 49,397,000 |
Percent of ABR | 13.70% |
Geographic Concentration Risk | Georgia | |
Concentration Risk [Line Items] | |
Total ABR | $ 26,570,000 |
Percent of ABR | 7.40% |
Geographic Concentration Risk | Florida | |
Concentration Risk [Line Items] | |
Total ABR | $ 25,512,000 |
Percent of ABR | 7.10% |
Geographic Concentration Risk | Indiana | |
Concentration Risk [Line Items] | |
Total ABR | $ 23,379,000 |
Percent of ABR | 6.50% |
Geographic Concentration Risk | Arizona | |
Concentration Risk [Line Items] | |
Total ABR | $ 21,542,000 |
Percent of ABR | 6.00% |
Geographic Concentration Risk | Other | |
Concentration Risk [Line Items] | |
Total ABR | $ 214,574,000 |
Percent of ABR | 59.30% |
Credit Concentration - Additional Information (Details) - Sales Revenue, Services, Net - Customer Concentration Risk |
3 Months Ended |
---|---|
Mar. 31, 2023
Rate
| |
Concentration Risk [Line Items] | |
Percent of ABR | 100.00% |
Top five tenant relationships | |
Concentration Risk [Line Items] | |
Percent of ABR | 19.80% |
CHI Portfolio | |
Concentration Risk [Line Items] | |
Percent of ABR | 14.80% |
Earnings Per Share - Schedule of Earnings Per Share and Earnings Per Unit (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|||
Numerator for earnings per share - basic: | ||||
Net income | $ 10,669 | $ 13,943 | ||
Net income attributable to noncontrolling interests: | ||||
Operating Partnership | (423) | (692) | ||
Partially owned properties | [1] | (44) | (159) | |
Net income attributable to common shareholders | 10,202 | 13,092 | ||
Numerator for earnings per share - diluted: | ||||
Numerator for earnings per share - basic | 10,202 | 13,092 | ||
Noncontrolling interest - Operating Partnership income | 423 | 692 | ||
Numerator for earnings per share - diluted | $ 10,625 | $ 13,784 | ||
Denominator for earnings per share - basic and diluted: | ||||
Weighted average number of shares outstanding - basic (in shares) | 237,484,043 | 225,069,208 | ||
Effect of dilutive securities: | ||||
Noncontrolling interest - Operating Partnership units (in shares) | 9,842,219 | 11,912,099 | ||
Denominator for earnings per share - diluted (in shares) | 248,756,672 | 238,340,243 | ||
Earnings per share - basic (in dollars per share) | $ 0.04 | $ 0.06 | ||
Earnings per share - diluted (in dollars per share) | $ 0.04 | $ 0.06 | ||
Restricted common shares | ||||
Effect of dilutive securities: | ||||
Restricted common shares/units (in shares) | 130,172 | 104,910 | ||
Restricted share units | ||||
Effect of dilutive securities: | ||||
Restricted common shares/units (in shares) | 1,300,238 | 1,254,026 | ||
|
Subsequent Events - Narrative (Details) $ in Millions |
1 Months Ended | 3 Months Ended |
---|---|---|
May 04, 2023
USD ($)
healthcareproperty
earn-outAgreement
|
Mar. 31, 2023
USD ($)
|
|
Term Loan | ||
Subsequent Event [Line Items] | ||
Payments for (proceeds from) loans receivable | $ 5.4 | |
Subsequent Event | ||
Subsequent Event [Line Items] | ||
Payments for (proceeds from) loans receivable | $ 0.8 | |
Subsequent Event | Two Medical Office Facilities in 2023 | ||
Subsequent Event [Line Items] | ||
Number of operating healthcare properties | healthcareproperty | 2 | |
Asset acquisition, consideration transferred | $ 1.4 | |
Subsequent Event | InterMed MOB - Davis Joint Venture | ||
Subsequent Event [Line Items] | ||
Asset acquisition, consideration transferred | $ 2.0 | |
Number of earn-out agreements | earn-outAgreement | 2 | |
Subsequent Event | InterMed MOB - Davis Joint Venture | Term Loan | ||
Subsequent Event [Line Items] | ||
Payments for (proceeds from) loans receivable | $ 3.4 |
G04K3\YX[?%H1U%HR"<>JOMRT>"-J1/NFE3XZ0WIXY0AM32L7^X%&U
M%MK10=TM>;PE*0ZZWPOQ;XG<<1#W#N+C'6 =U8:*@HG5(0OQ/\+"Z"*ZC"^2
MRQ<6AB*C\#(,HCT6DMY" %(;]7P/5?!- J7GX)X_ANF\S--=F(!UEF
M^69??838(XM4[02F9C,VKL>:$'-")@TE;R)M45&^$Z5E?Q/_0#3O)DNZBT92^(D&2PL)D7C
M.;ZP287$6Y%P %8$39H>T#<"US=?J*&9KP[53(-EOX)F/@A4O[N0ZQ[UP,0('0HOT8!Q)BT*JDA2JP@W>OJ2/CB9TH $F
M%%.' CW^#LY2H/89TGH+UY"> ?Y,K%'3MW/W( B7&>^L2;.).L>^MFM5K[R6:"9"G1)D3 12(80HT5!07)MT=\CUH'(;;Q]T$SFHX,Q-/Q4?WGH7:N92,]OK?Z
M+U53LXK*"&K IB5%H? (.H
M4:.[#=2H7#++9A.MUJ"=-[&Y19-J@R9Q7+I'>;":K)QP=K9$S9^9NQD#1X]L
M)= <3WQ+S,[N)QW+HF6)WF&)X59)6QBXEBFFNWB?%/6RHHVL1;27\);I <3A
M"41!%._AB_LTXX8O_F^:<".-U375E84E6L8%_)BOZ(CJX^=;F;?$P[>)7<^,
M3<42G'K4% ;U,WJSPP_A:7"Y1_:PESW=+?9!0 71@ !@ !X;"]W;W)K=*5V[6! L)-%\\N_MX;H#8!Y
M\ &T'4"' YAC0-@."&M%&V2U6C>\XJN+4MV3TDC#;.:BMDT]&K21A5G&+U4)
M_Y4PKEI=JT*K7&:\$AGY4L$/K%&EB=J0:ZZWY!VLLR93\O7+#7GQ\Z_D9R(+
M\N=6'30O,GTQJP"#F6F6MN][T[R/.MX7D@^JJ+::O"TRD9V.GP'V3@'ZJ, ;
MZIWP R]?D3!X2>BZQ\?3CUPPLZ>83U?Z+*G-=JF5#OR:2]*7LGBCEP9
MAY65%/HU9K9F6H9/:S;S:[WGJ;B*TW[)_S8S ]M*2H= N(?
M--G,H[?X3U'
'+;%G5
M.T9*JIE!"\
\1PU4XEYUX69
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MQ91)R0H]7% L)EP1X/Z,X27:3)2 [G?6];]02P,$% @ ^H&D5O("?5\,
M P FP8 !D !X;"]W;W)K